Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?
作者信息
Inoue Yusuke
机构信息
Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
出版信息
Transl Lung Cancer Res. 2024 Apr 29;13(4):947-951. doi: 10.21037/tlcr-24-63. Epub 2024 Apr 18.
Abstract
摘要
相似文献
1
Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?免疫检查点抑制剂的皮下给药：取代静脉给药的新途径？
Transl Lung Cancer Res. 2024 Apr 29;13(4):947-951. doi: 10.21037/tlcr-24-63. Epub 2024 Apr 18.
2
Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.风险因素、透明质酸酶表达和临床免疫原性的重组人透明质酸酶 PH20，一种能够进行皮下药物给药的酶。
AAPS J. 2022 Oct 20;24(6):110. doi: 10.1208/s12248-022-00757-3.
3
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.一项评估重组人透明质酸酶PH20静脉注射于健康志愿者的安全性、耐受性、药代动力学和药效学的I期研究。
Curr Ther Res Clin Exp. 2020 Aug 19;93:100604. doi: 10.1016/j.curtheres.2020.100604. eCollection 2020.
4
ENHANZE drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20.增强型药物输送技术：一种使用重组人透明质酸酶 PH20 进行皮下给药的新方法。
Drug Deliv. 2019 Dec;26(1):98-106. doi: 10.1080/10717544.2018.1551442.
5
The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies.重组人透明质酸酶 PH20 在非临床模型中的安全性：毒理学、药理学概述及抗 PH20 抗体的影响。
J Control Release. 2024 Oct;374:369-383. doi: 10.1016/j.jconrel.2024.07.062. Epub 2024 Aug 23.
6
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.用于皮下药物递送的重组人透明质酸酶 PH20 的安全性。
Expert Opin Drug Deliv. 2021 Nov;18(11):1673-1685. doi: 10.1080/17425247.2021.1981286. Epub 2021 Sep 29.
7
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.在小型猪和健康志愿者中，皮下给予重组人透明质酸酶后昂丹司琼的耐受性和药代动力学特性。
Clin Ther. 2014 Feb 1;36(2):211-24. doi: 10.1016/j.clinthera.2013.12.013. Epub 2014 Jan 31.
8
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model.在小型猪模型中，用重组人透明质酸酶 PH20 皮下给药，确定最大流速与粘度之间的预测关系。
Drug Deliv. 2023 Dec;30(1):2252999. doi: 10.1080/10717544.2023.2252999.
9
Use of computed tomography to assess subcutaneous drug dispersion with recombinant human hyaluronidase PH20 in a swine model.使用计算机断层扫描评估在猪模型中使用重组人透明质酸酶 PH20 进行皮下药物分布。
J Pharmacol Toxicol Methods. 2020 Nov-Dec;106:106936. doi: 10.1016/j.vascn.2020.106936. Epub 2020 Oct 22.
10
A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration.衰老对重组人透明质酸酶PH20给药后真皮透明质酸特性及重建影响的临床前研究
Dermatol Ther (Heidelb). 2020 Jun;10(3):503-513. doi: 10.1007/s13555-020-00380-0. Epub 2020 May 2.
引用本文的文献
1
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.即将到来：为初治卡介苗无反应的高危非肌肉浸润性膀胱癌患者提供新兴疗法的全球多学科视角
Oncol Ther. 2025 Apr 17. doi: 10.1007/s40487-025-00334-6.
2
Cost-Effective and Sustainable Drug Use in Hospitals: A Systematic and Practice-Based Approach.医院中具有成本效益且可持续的药物使用：一种基于系统和实践的方法。
Appl Health Econ Health Policy. 2025 Mar;23(2):183-195. doi: 10.1007/s40258-024-00937-6. Epub 2024 Dec 19.
本文引用的文献
1
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access.推进生物疗法的皮下给药方案：加速市场准入的临床策略。
BioDrugs. 2024 Jan;38(1):23-46. doi: 10.1007/s40259-023-00626-1. Epub 2023 Oct 13.
2
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
3
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.IMscin001 第二部分：一项随机、III 期、开放性、多中心研究，评估阿特珠单抗皮下与静脉给药治疗既往治疗的局部晚期或转移性非小细胞肺癌的药代动力学、疗效、免疫原性和安全性，并与其他已批准适应症进行药代动力学比较。
Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1.
4
Immune Checkpoint Inhibitors - The Need for Innovation.免疫检查点抑制剂——创新的必要性。
N Engl J Med. 2023 Apr 20;388(16):1529-1532. doi: 10.1056/NEJMsb2300232.
5
Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology.药物动力学特征、皮下注射单克隆抗体在肿瘤学中的获益和障碍。
J Oncol Pharm Pract. 2023 Mar;29(2):431-440. doi: 10.1177/10781552221137702. Epub 2022 Nov 8.
6
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.头颈部癌的低剂量免疫疗法：一项随机研究。
J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20.
7
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.抗阿特珠单抗的高抗体水平与肝癌患者的临床结局和 T 细胞反应的相关性。
JAMA Oncol. 2022 Dec 1;8(12):1825-1829. doi: 10.1001/jamaoncol.2022.4733.
8
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
9
Subcutaneous Atezolizumab: A Jab Without a Benefit.皮下注射阿替利珠单抗：一种无益处的注射方式。
Clin Pharmacol Drug Dev. 2022 Jan;11(1):134-135. doi: 10.1002/cpdd.1061. Epub 2021 Dec 23.
10
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery.用于皮下药物递送的重组人透明质酸酶 PH20 的安全性。
Expert Opin Drug Deliv. 2021 Nov;18(11):1673-1685. doi: 10.1080/17425247.2021.1981286. Epub 2021 Sep 29.
Zotero 插件